QualityDipStocks / Health Care · Pharmaceuticals
UroGen Pharma URGN
Outside our quality screen, so we don’t track its dips. It’s 32% below its 52-week high.
Outside our quality screen, 17% under its Market Value. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Down 32% from its 52-week high while revenue grew 100%
- Revenue up 100% in a year, top 3% of the 2194 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $41.41price −17%
- Off 52-wk high
- −32%
- Risk vs market
- Above marketbeta 1.20
52-week range 52% of the way from its 52-week low to its high
Price $34.36Market Value $41.41
4 bullish · 5 bearish See why
Repriced or dip?
Mixed signals
The price is 32% below its 52-week high (Aug 19), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts, shares outstanding more shares, each owns less.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, operating margin 0.0 pts, shares outstanding more shares, each owns less), others slipped. The price is 32% below its 52-week high.
The price is 32% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$189M → $189M (0.0%)about the same
- Operating margin−35.3% → −35.3% (0.0 pts)held up
- Shares outstanding+1.2% (more shares, each owns less)held up
- Net cash (cash minus debt)0.0% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −32%, sector median −2% since Aug 19changed
- Price fall vs business numbersprice −32%, revenue/EPS/FCF median 0% (shown, not scored)
No new report since the high (Aug 19, 2026): the business numbers are the same as then, so this read is capped at 65. Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for URGN: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much URGN moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 4.9× the S&P 500’s.
- Beta vs S&P 500
- 1.20
- Volatility
- 63% vs 13% SPY
- Correlation SPY
- 0.25
- Correlation QQQ
- 0.23
How it ranks
Where URGN stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 4 measures
- Free cash flow yield−9.4% · free cash flow vs market capLowest 4%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Revenue growth, last 12 months+100% · vs the 12 months beforeTop 2%of 2,184
- Operating margin−35% · of sales kept as operating profitLowest 4%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $41.41
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
GrowthSales grew 100% to $189M over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 19% a year from FY2022 to FY2025.
ProfitabilityGross margin of 91%, above the 65% median for the 195 Health Care companies we cover.
ValuationTrades 17.0% below its Market Value of $41.41, the average price paid since the Aug 5 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$159M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityOperating margin narrowed to −113.7% in FY2025 from −79.2% in FY2023 (SEC filings).
ProfitabilityLost $98M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −35% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: no positive free cash flow; no return-on-capital data; debt load unclear or high.
All fundamentals
FCF yield -9.4% · Sales +100%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −9.4%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- 9.01×
- Price / book
- n/anot reported in its SEC filings
- Market cap
- $1.7Blisted
- Enterprise value
- $1.8B
Growth
- Revenue, 12 months
- $189M
- Sales growth, 12 months
- +100.3%vs the 12 months before
- Sales growth, 3 yrs
- +19.5%/yrfrom FY2022
- Diluted EPS, 12 months
- n/anot reported in its SEC filings
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$98M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- 90.8%
- Operating margin
- −35.3%
- Net margin
- −51.7%
- FCF margin
- −84.3%
- Return on equity
- n/anegative shareholder equity
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $109M
- Total debt
- $200M
- Net cash
- −$91M
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$159M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- $16M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From UroGen Pharma’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.2B · Sales +199%
- Free cash flow, 12 months−$0.2B
- Free-cash-flow yield-9.4%
- Gross margin91%
- Operating margin0%
- Sales growth (latest quarter vs year-ago quarter)+199%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $34.36
- 52-wk lowlowest close, 1 year$17.00−50.5%
- PriceMon Nov 2 close$34.36you are here
- Market Valueavg paid since Aug 5$41.41+20.5%
- 52-wk highhighest close, 1 year$50.29+46.4%
Momentum & 52-week range
RSI 38 · 5 days +0.9%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 4
- DateWed Nov 4, before the open
- Consensus EPS$0.05
- Year-ago EPS($0.69)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
URGN is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on UroGen Pharma in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.